24/7 Market News Snapshot 02 December, 2024 – Revelation Biosciences, Inc. Common Stock (NASDAQ:REVB)

December 2, 2024

DENVER, Colo., 02 December, 2024 (247marketnews.com) – (NASDAQ:REVB) are discussed in this article.
Revelation Biosciences, Inc. is experiencing a notable surge in its market performance, with its stock trading at $1.136, up 49.47% from the previous close of $0.760, fueled by a trading volume of approximately 3.93 million shares. This significant price increase indicates strong investor interest and reflects a growing optimism regarding the company’s future in the biopharmaceutical sector.

In a pivotal development, Revelation has secured regulatory acceptance from the United States Food and Drug Administration for its investigational new drug (IND) application concerning Gemini. This marks a crucial advancement for the company, allowing it to commence a Phase 1b clinical study focused on evaluating Gemini’s efficacy as a preconditioning treatment for chronic kidney disease (CKD). The upcoming multi-site, placebo-controlled trial will enroll up to 40 participants across five cohorts, primarily assessing the safety and tolerability of Gemini. Additionally, the study will monitor pharmacokinetics and the treatment’s ability to modulate the innate immune response in stress conditions, utilizing biomarkers for efficacy evaluation.

The anticipated results from this Phase 1b study could lay the groundwork for a subsequent Phase 2 trial aimed at examining Gemini’s potential to alleviate the incidence and severity of acute kidney injury (AKI) in patients undergoing coronary artery bypass grafting or cardiac valve surgeries.

James Rolke, CEO of Revelation, expressed pride in reaching this significant milestone, emphasizing the innovative aspects of Gemini. He reiterated the company’s commitment to advancing patient outcomes through cutting-edge research and expressed eagerness to initiate the Phase 1b clinical study shortly. With Gemini’s promising formulation targeting inflammatory damage, Revelation is positioned as a leader in biopharmaceutical innovation, dedicated to enhancing therapeutic pathways and improving patient care.

Related news for (REVB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.